Skip to main content
The William Harvey Research Institute - Faculty of Medicine and Dentistry

Dr Manish Saxena

Manish

Clinical Co-Director, William Harvey Clinical Research Centre and Deputy Director Research, Barts Health NHS Trust and QMUL

Centre: Clinical Pharmacology and Precision Medicine, Clinical Research Centre

Email: m.saxena@qmul.ac.uk
Telephone: +44(0) 20 7882 3856
X: @DrManishNSaxena

Profile

Dr Saxena completed MBBS in 1996 and has been practising medicine for over 25 years. He completed a Master’s degree in Health Care Research and Clinical Drug Development with distinction from Queen Mary University of London. He is Deputy Director for Research for Barts Health NHS Trust/QMUL and Clinical Co-Director at the William Harvey Clinical Research Centre. He works at Barts Hypertension Clinic as a European Accredited specialist in hypertension. Dr Saxena has worked with the Health Research Authority as an expert member for over 12 years and has been chair of the National Research ethics committee for over 7 years. He is part of the National Institute for Health and Care Research (NIHR) leadership group as Speciality Research Lead for Diabetes for North Thames CRN. He is Academic Lead for Innovation and Commercial Partnerships for Barts Faculty of Medicine.

Research

Group members 

Armida Balawon, Ania Michalska, Francis Galera, Benildo Quiros, Aaron Jairo Oblena, Arooj Ayub, Brenda Roberts, Rizwana Ayub

Summary 

Dr Saxena is a cardiovascular (CV) physician passionate about developing novel therapies for CV prevention and treatment. As UK Chief Investigator and Barts lead, he leads on several studies in high-risk patients with dyslipidaemia (with second generation PCSK9i such as Inclisiran and oral PCSK9i, Bempedoic Acid, CETP modulators); in T2DM and CHF (SGLT2i, GLP-1, Aldose reductase inhibitors). He runs studies in Hypertension pioneering pharmacotherapy (SiRNA) and novel device therapies such as Renal Denervation, Carotid sinus modulation and Arterio-venous coupler besides collaborating on novel BP monitoring technologies such as Life light using remote PPG technology. He also works with patients with autonomic dysfunction and has run studies in patients with neurogenic orthostatic hypotension. His work also includes studies in other CV therapeutics involving anti-platelets, new oral anti-coagulants, dementia prevention and treatment.

Memberships and awards

  • Member European Society of HTN
  • Member European Society of Cardiology
  • Member Joint British and Irish Hypertension Society

Publications

  • Watts GF, Ballantyne CM, Blanco Echevarria A et al. (2026). Plozasiran for Severe Hypertriglyceridemia and Risk of Pancreatitis. nameOfConference


  • Saxena M (2026). RNAi Targeting Hepatic AGT to Block RAAS Pathway in Hypertension.. nameOfConference


  • Brandts JM, Saxena M, Costa-Scharplatz M et al. (2026). Mobilizing core and country-tailored implementation strategies to accelerate Lipoprotein(a) testing across Europe: findings from the Lp(a)CCELERATE contextual analysis. nameOfConference


    QMRO: qmroHref
  • Pagidipati N, Weber M, Saxena M et al. (2026). Zilebesiran in combination with a diuretic in patients with uncontrolled hypertension: a subgroup analysis from the Phase 2 KARDIA-3 trial. nameOfConference


    QMRO: qmroHref
  • Gupta A, Collier D, Steckelmacher J et al. (2026). Safety, Acceptability and Efficacy of Noninvasive Transcutaneous-Autonomic Neuromodulation in Uncontrolled Hypertension.. nameOfConference


  • Saxena M, Zambon A, Brandts J et al. (2026). LP(A)CCELERATE: CONTEXTUAL ANALYSIS TO INTEGRATE LP(A) TESTING IN ROUTINE CARDIOVASCULAR CARE USING IMPLEMENTATION SCIENCE. nameOfConference


    QMRO: qmroHref
  • Pagidipati N, Weber M, Saxena M et al. (2026). KARDIA-3: ZILEBESIRAN AS ADD-ON THERAPY IN ADULTS WITH HYPERTENSION AND ESTABLISHED CARDIOVASCULAR DISEASE OR HIGH CARDIOVASCULAR RISK WITH AND WITHOUT CHRONIC KIDNEY DISEASE. nameOfConference


    QMRO: qmroHref
  • Desai AS, SAXENA M, Granger CB et al. (2026). 26-A-15266-ACC POOLED SAFETY ANALYSIS OF ZILEBESIRAN, AN INVESTIGATIONAL LONG-ACTING RNA INTERFERENCE THERAPEUTIC, FROM PHASE 2 STUDIES IN PATIENTS WITH HYPERTENSION. nameOfConference


    QMRO: qmroHref
  • Catapano AL, Mikhailova E, Navar AM et al. (2026). Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies A Phase 3 Randomized Clinical Trial. nameOfConference


  • Azizi M, Brown JM, Dwyer JP et al. (2026). Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial. nameOfConference


    QMRO: qmroHref
View profile publication page

Collaborators

  • Prof Anoop Chauhan, MBE, Director Research & Innovation, Portsmouth Hospitals NHS Trust
  • Prof Melvin Lobo, Director Barts BP Services
  • Prof Feng He, Prof of Global Health Research, Wolfson Institute
  • Dr David Collier, Deputy Director, Barts CTU
  • Antonio Sotiris, Chief Pharmacist Barts Hospital
  • Oxford Clinical Trials Unit
  • Blood Pressure UK

News

June 2022

May 2022

April 2022

December 2021

June 2021

November 2010

Back to top